JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 20, 2004; DOI: 10.1124/jpet.103.062620


0022-3565/04/3093-978-986$20.00
JPET 309:978-986, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.062620v1
309/3/978    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Y.-M.
Right arrow Articles by Hsieh, B.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Y.-M.
Right arrow Articles by Hsieh, B.-S.

CARDIOVASCULAR

Dual Regulation of Tumor Necrosis Factor-{alpha}-Induced CCL2/Monocyte Chemoattractant Protein-1 Expression in Vascular Smooth Muscle Cells by Nuclear Factor-{kappa}B and Activator Protein-1: Modulation by Type III Phosphodiesterase Inhibition

Yung-Ming Chen, Wen-Chih Chiang, Shuei-Liong Lin, Kwan-Dun Wu, Tun-Jun Tsai, and Bor-Shen Hsieh

Department of Medicine, National Taiwan University Hospital and College of Medicine National Taiwan University, Taipei, Taiwan

Monocyte/macrophage infiltration to the subendothelial space of arterial wall is a critical initial step in atherogenesis, in which CC chemokine ligand 2 (CCL2)/monocyte chemoattractant protein-1 (MCP-1) is thought to play a key role. This study investigated the effectiveness of phosphodiesterase inhibitors, including the nonselective pentoxifylline (PTX) and the selective type III (cilostamide) and type IV (denbufylline) inhibitors, on cytokine-induced CCL2/MCP-1 production in cultured rat vascular smooth muscle cells (VSMCs), and the signal transduction mechanisms whereby they act. Our results showed that tumor necrosis factor (TNF)-{alpha} induced a marked increase in CCL2/MCP-1 production in dose- and time-dependent manners. 2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (PD98059), 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene (U0126) [both inhibitors of p42/44 mitogen-activated protein kinase (MAPK) kinase], and anthra[1hyphen]9-cd]pyrazol-6(2H)-one (SP600125) [an inhibitor of c-Jun NH2-terminal kinases (JNKs)] attenuated TNF-{alpha}-induced CCL2/MCP-1 production, without affecting I-{kappa}B{alpha} degradation or p65/nuclear factor-{kappa}B (NF-{kappa}B) nuclear translocation. PD98059 abolished TNF-{alpha}-activated p42/44 MAPK phosphorylation and c-Fos up-regulation, whereas SP600125 inhibited TNF-{alpha}-activated JNK and c-Jun phosphorylation. The NF-{kappa}B inhibitor carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG132) attenuated TNF-{alpha}-induced CCL2/MCP-1 production in the presence of increased phospho-JNK and phospho-c-Jun levels. When SP600125 was added simultaneously, MG132 completely inhibited TNF-{alpha}-induced CCL2/MCP-1 production. Finally, the pretreatment of VSMCs with PTX or cilostamide, but not denbufylline, reduced TNF-{alpha}-induced CCL2/MCP-1 production, which was preceded by attenuation of p65/NF-{kappa}B nuclear translocation, p42/44 MAPK, and JNK-c-Jun phosphorylation, and c-Fos up-regulation. These data indicate that TNF-{alpha}-stimulated CCL2/MCP-1 production in rat VSMCs is dually regulated by activator protein-1 (AP-1) and NF-{kappa}B pathways, and inhibition of type III phosphodiesterase contributes substantially to the suppressive effect of PTX on CCL2/MCP-1 production via down-regulation of AP-1 and NF-{kappa}B signals.


Received November 6, 2003; accepted February 19, 2004.

Address correspondence to: Dr. Kwan-Dun Wu, Department of Medicine, National Taiwan University Hospital, 7, Chung-Shan South Rd., Taipei, 10016, Taiwan. E-mail: kdw{at}ha.mc.ntu.edu.tw.




This article has been cited by other articles:


Home page
J Mol EndocrinolHome page
S. X Zhang, J. J Wang, A. Dashti, K. Wilson, M.-H. Zou, L. Szweda, J.-X. Ma, and T. J Lyons
Pigment epithelium-derived factor mitigates inflammation and oxidative stress in retinal pericytes exposed to oxidized low-density lipoprotein
J. Mol. Endocrinol., September 1, 2008; 41(3): 135 - 143.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Tanimoto, Y. Murata, K.-Y. Wang, M. Tsutsui, K. Kohno, and Y. Sasaguri
Monocyte Chemoattractant Protein-1 Expression Is Enhanced by Granulocyte-Macrophage Colony-stimulating Factor via Jak2-Stat5 Signaling and Inhibited by Atorvastatin in Human Monocytic U937 Cells
J. Biol. Chem., February 22, 2008; 283(8): 4643 - 4651.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
H. Sakai, S. Otogoto, Y. Chiba, K. Abe, and M. Misawa
Involvement of p42/44 MAPK and RhoA protein in augmentation of ACh-induced bronchial smooth muscle contraction by TNF-{alpha} in rats
J Appl Physiol, December 1, 2004; 97(6): 2154 - 2159.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.